Document Detail


Genotype and phenotype relationship in drug metabolism.
MedLine Citation:
PMID:  17117716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Today, the relationships between dosage requirements and genetic variations in drug-metabolizing enzymes such as cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C19 or in drug transporters such as p-glycoprotein (ABCB1) and OATP-C (SLC21A6) are substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better because of higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. In some cases, genetic tests can help distinguish between responders and nonresponders of a specific drug treatment, and genotype-based dosage is possible.
Authors:
I Roots; G Laschinski; F Arjomand-Nahad; J Kirchheiner; D Schwarz; J Brockmöller; I Cascorbi; T Gerloff
Related Documents :
18085566 - Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norep...
16968526 - Safety concerns on the development of novel therapeutic drugs.
19509486 - Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug trea...
11337936 - Functional characterization of human n-acetyltransferase 2 (nat2) single nucleotide pol...
22952046 - Drug-drug interactions between warfarin and psychotropics: updated review of the litera...
3950006 - Psychosocial factors in outcome in two opiate addiction treatments.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Ernst Schering Research Foundation workshop     Volume:  -     ISSN:  0947-6075     ISO Abbreviation:  Ernst Schering Res. Found. Workshop     Publication Date:  2007  
Date Detail:
Created Date:  2006-11-22     Completed Date:  2006-12-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9422786     Medline TA:  Ernst Schering Res Found Workshop     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  81-100     Citation Subset:  IM    
Affiliation:
Institut für Klinische Pharmakologie, Charité, Universitätsmedizin Berlin, Germany. ivar.roots@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aryl Hydrocarbon Hydroxylases / metabolism
Chemistry, Pharmaceutical / methods*
Cytochrome P-450 CYP1A1 / genetics
Dose-Response Relationship, Drug
Drug Industry / methods*
Estrogens / metabolism
Genotype
Humans
Kinetics
Mixed Function Oxygenases / metabolism
Pharmacogenetics / methods
Pharmacology, Clinical
Phenotype
Polymorphism, Genetic
Receptors, Serotonin, 5-HT3 / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Estrogens; 0/Receptors, Serotonin, 5-HT3; EC 1.-/Mixed Function Oxygenases; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C19 protein, human; EC 1.14.14.1/Cytochrome P-450 CYP1A1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Experiences with dose finding in patients in early drug development: the use of biomarkers in early ...
Next Document:  Clinical trials in elderly patients.